uniQure QURE 深 沪
等待开盘 12-20 09:30:00 美东时间
23.975
+0.045
+0.19%
华盛通- 最 高28.50
- 今 开23.72
- 成交量 338.20万股
- 最 低 19.29
- 昨 收 23.93
- 总市值 11.18亿
- 52周最高 71.50
- 市盈率 静 3.41
- 换手率 7.25%
- 52周最低 7.76
- 委 比 42.69%
- 总股本 4664.76万
- 历史最高 82.49
- 量 比 0.88
- 振 幅 38.49%
- 历史最低 1.10
- 每 手 1
- 风险率 14.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
A Glimpse of uniQure's Earnings Potential
uniQure (NASDAQ:QURE) will release its quarterly earnings report on Monday, 202...
11-08 01:05
Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection
Biohaven stock plunged after the FDA rejected Vyglxia for spinocerebellar ataxia, prompting major R&D cuts and a William Blair downgrade.
11-06 01:53
Gold Edges Higher; ISM Manufacturing PMI Falls In October
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index fa...
11-04 03:23
UniQure Shares Drop After FDA Shifts Stance On Huntington's Gene Therapy Data
UniQure shares fell after the FDA questioned the adequacy of data supporting its AMT-130 gene therapy for Huntington's disease, delaying BLA plans.
11-04 02:04
Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining mor...
11-03 21:14
华福证券-生物医药行业：看好创新药产业趋势，关注ESMO和医保谈判-251014
（来源：研报虎） 创新药大事回顾：1)uniQure基因疗法AMT-130亨廷顿病I/II期临床取得顶线结果：亨廷顿病是一种罕见常染色体显性遗传病，由位于...
10-14 17:58
生物技术公司uniQure将公开发行股票筹资3亿美元
生物技术公司uniQure(QURE)早盘下跌2.6%，该公司将扩模后的3亿美元公开发行定价为每股47.50美元。所筹资金将支持公司持续进行临床试验和产品开发，巩固其在基因治疗市场的地位。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
09-26 22:49
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
uniQure appoints Kylie O’Keefe as Chief Customer and Strategy Officer to lead the commercialization of AMT-130, a gene therapy for Huntington’s disease. With extensive experience in rare diseases and gene therapy, O’Keefe will oversee global commercial strategy and execution for AMT-130, aiming for U.S. launch in 2026. Her leadership is expected to advance uniQure’s mission of addressing severe unmet medical needs.
06-11 12:00
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
uniQure公司宣布其基因疗法AMT-130在治疗亨廷顿病方面的监管进展，与FDA达成一致，计划于2026年第一季度提交生物制品许可申请(BLA)。
06-02 11:05
